{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:34:56Z","timestamp":1789684496438,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014425","name":"Acorda Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaad.2023.03.051","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:16:00Z","timestamp":1681298160000},"page":"261-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus"],"prefix":"10.1016","volume":"89","author":[{"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Munera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jaad.2023.03.051_bib1","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/ndt\/gfl461","article-title":"Pruritus in haemodialysis patients: international results from the dialysis outcomes and practice patterns study (DOPPS)","volume":"21","author":"Pisoni","year":"2006","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"10.1016\/j.jaad.2023.03.051_bib2","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2215\/CJN.03280317","article-title":"International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis","volume":"12","author":"Rayner","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2023.03.051_bib3","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ckj\/sfab167","article-title":"Clinical management of chronic kidney disease-associated pruritus: current treatment options and future approaches","volume":"14","author":"Lipman","year":"2021","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.051_bib4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11255-015-1208-5","article-title":"Epidemiology and determinants of pruritus in pre-dialysis chronic kidney disease patients","volume":"48","author":"Solak","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"10.1016\/j.jaad.2023.03.051_bib5","doi-asserted-by":"crossref","first-page":"c74","DOI":"10.1159\/000183177","article-title":"Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool","volume":"111","author":"Murphy","year":"2009","journal-title":"Nephron Clin Pract"},{"issue":"5","key":"10.1016\/j.jaad.2023.03.051_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.09600818","article-title":"Pruritus and patient reported outcomes in non-dialysis CKD","volume":"14","author":"Sukul","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jaad.2023.03.051_bib7","first-page":"1","article-title":"Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms","volume":"7","author":"Ramakrishnan","year":"2013","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.051_bib8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1159\/000490689","article-title":"Uremic pruritus is associated with two-year cardiovascular mortality in long term hemodialysis patients","volume":"43","author":"Weng","year":"2018","journal-title":"Kidney Blood Press Res"},{"issue":"9","key":"10.1016\/j.jaad.2023.03.051_bib9","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2020.04.027","article-title":"CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management","volume":"5","author":"Verduzco","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jaad.2023.03.051_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/IJNRD.S108045","article-title":"Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges","volume":"10","author":"Shirazian","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"12","key":"10.1016\/j.jaad.2023.03.051_bib11","first-page":"Cd011393","article-title":"Interventions for itch in people with advanced chronic kidney disease","volume":"12","author":"Hercz","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jaad.2023.03.051_bib12","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2215\/CJN.00100110","article-title":"A longitudinal study of uremic pruritus in hemodialysis patients","volume":"5","author":"Mathur","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.jaad.2023.03.051_bib13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.03.051_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jdin.2022.04.003","article-title":"Understanding the patient experience of living with notalgia paresthetica: a qualitative interview study","volume":"8","author":"Bacci","year":"2022","journal-title":"JAAD Int"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.051_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.051_bib16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaad.2020.06.991","article-title":"Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus","volume":"84","author":"Vernon","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2023.03.051_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100513","article-title":"Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program","volume":"4","author":"Fishbane","year":"2022","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.jaad.2023.03.051_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ekir.2020.01.006","article-title":"Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients","volume":"5","author":"Fishbane","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.051_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.051_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2215\/CJN.13010921","article-title":"Trajectories of uremic symptom severity and kidney function in patients with chronic kidney disease","volume":"17","author":"Wulczyn","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.051_bib21","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1053\/j.ajkd.2022.01.416","article-title":"Burden of pruritus in patients with chronic kidney disease: a National Kidney Foundation patient survey [abstract 411]","volume":"79","author":"Torres","year":"2022","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223005868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223005868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:22:42Z","timestamp":1759274562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223005868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0190962223005868"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.051","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}